Elite Pharmaceuticals Inc (ELTP)

[springnut]

As an addendum to the summary, I would be remiss in not acknowledging that my interest in LCI was born of an investment in a small company that is now an LCI business partner. As noted in the discussion of Threat Three in the article, that company is Elite Pharma (OTCQB:ELTP), a small OTC company that is extremely undervalued and, likely, worthy of an article for its a major turnaround. But for now, it suffices to say Elite has multiple drugs being commercialized by LCI, including generic Adderall. Moreover, Elite and its privately held partner SunGen Pharma are expecting FDA approval later this month for an extended-release CNS ANDA that, according to IQVIA data, has an annual market of $1.6B and will be commercialized by Lannett.

Indeed, this shows how astutely LCI is building its business, with key partnerships and targeted internal development. Without question, this should translate well into future revenue growth for the company. While growth does not cure all ills or ameliorate all threats, it does rhyme.


https://seekingalpha.com/article/4311033-lannett-building-success-one-step-time